2023

1.Bispecific PD1-IL2v and anti-PD-L1 break tumor immunity resistance by enhancing stem-like tumor-reactive CD8⁺ T cells and reprogramming macrophages.
Tichet M, Wullschleger S, Chryplewicz A, Fournier N, Marcone R, Kauzlaric A, Homicsko K, Deak LC, Umaña P, Klein C, Hanahan D.
Immunity. 2023 Jan 10;56(1):162-179.e6. doi: 10.1016/j.immuni.2022.12.006.
PMID: 36630914

2022

2. Aberrant hyperexpression of the RNA binding protein FMRP in tumors mediates immune evasion.
Zeng Q, Saghafinia S, Chryplewicz A, Fournier N, Christe L, Xie YQ, Guillot J, Yucel S, Li P, Galván JA, Karamitopoulou E, Zlobec I, Ataca D, Gallean F, Zhang P, Rodriguez-Calero JA, Rubin M, Tichet M, Homicsko K, Hanahan D.
Science. 2022 Nov 18;378(6621):eabl7207. doi: 10.1126/science.abl7207. Epub 2022 Nov 18.
PMID: 36395212

3. PD-1-cis IL-2R agonism yields better effectors from stem-like CD8⁺ T cells.
Codarri Deak L, Nicolini V, Hashimoto M, Karagianni M, Schwalie PC, Lauener L, Varypataki EM, Richard M, Bommer E, Sam J, Joller S, Perro M, Cremasco F, Kunz L, Yanguez E, Hüsser T, Schlenker R, Mariani M, Tosevski V, Herter S, Bacac M, Waldhauer I, Colombetti S, Gueripel X, Wullschleger S, Tichet M, Hanahan D, Kissick HT, Leclair S, Freimoser-Grundschober A, Seeber S, Teichgräber V, Ahmed R, Klein C, Umaña P.
Nature. 2022 Oct;610(7930):161-172. doi: 10.1038/s41586-022-05192-0. Epub 2022 Sep 28.
PMID: 36171284 Free PMC article.

4. Cancer cell autophagy, reprogrammed macrophages, and remodeled vasculature in glioblastoma triggers tumor immunity.
Chryplewicz A, Scotton J, Tichet M, Zomer A, Shchors K, Joyce JA, Homicsko K, Hanahan D.
Cancer Cell. 2022 Oct 10;40(10):1111-1127.e9. doi: 10.1016/j.ccell.2022.08.014. Epub 2022 Sep 15.
PMID: 36113478 Free PMC article.

2020

5. Myeloid Cells Orchestrate Systemic Immunosuppression, Impairing the Efficacy of Immunotherapy against HPV⁺ Cancers.
Galliverti G, Wullschleger S, Tichet M, Murugan D, Zangger N, Horton W, Korman AJ, Coussens LM, Swartz MA, Hanahan D.
Cancer Immunol Res. 2020 Jan;8(1):131-145. doi: 10.1158/2326-6066.CIR-19-0315. Epub 2019 Nov 26.
PMID: 31771984 Free PMC article.

2019

6. Cancer cell-derived long pentraxin 3 (PTX3) promotes melanoma migration through a toll-like receptor 4 (TLR4)/NF-κB signaling pathway.
Rathore M, Girard C, Ohanna M, Tichet M, Ben Jouira R, Garcia E, Larbret F, Gesson M, Audebert S, Lacour JP, Montaudié H, Prod’Homme V, Tartare-Deckert S, Deckert M.
Oncogene. 2019 Jul;38(30):5873-5889. doi: 10.1038/s41388-019-0848-9. Epub 2019 Jun 28.
PMID: 31253871

7. ALK7 Signaling Manifests a Homeostatic Tissue Barrier That Is Abrogated during Tumorigenesis and Metastasis.
Michael IP, Saghafinia S, Tichet M, Zangger N, Marinoni I, Perren A, Hanahan D.
Dev Cell. 2019 May 6;49(3):409-424.e6. doi: 10.1016/j.devcel.2019.04.015.
PMID: 31063757

2018

8. Nanoparticle Conjugation of Human Papillomavirus 16 E7-long Peptides Enhances Therapeutic Vaccine Efficacy against Solid Tumors in Mice.
Galliverti G, Tichet M, Domingos-Pereira S, Hauert S, Nardelli-Haefliger D, Swartz MA, Hanahan D, Wullschleger S.
Cancer Immunol Res. 2018 Nov;6(11):1301-1313. doi: 10.1158/2326-6066.CIR-18-0166. Epub 2018 Aug 21.
PMID: 30131378

9. Targeting the Proteasome-Associated Deubiquitinating Enzyme USP14 Impairs Melanoma Cell Survival and Overcomes Resistance to MAPK-Targeting Therapies.
Didier R, Mallavialle A, Ben Jouira R, Domdom MA, Tichet M, Auberger P, Luciano F, Ohanna M, Tartare-Deckert S, Deckert M.
Mol Cancer Ther. 2018 Jul;17(7):1416-1429. doi: 10.1158/1535-7163.MCT-17-0919. Epub 2018 Apr 27.
PMID: 29703842

10. Cellular endogenous NAD(P)H fluorescence as a label-free method for the identification of erythrocytes and reticulocytes.
Tauzin L, Campos V, Tichet M.
Cytometry A. 2018 Apr;93(4):472-479. doi: 10.1002/cyto.a.23351. Epub 2018 Feb 26.
PMID: 29480979

2016

11. SIGMAR1 Regulates Membrane Electrical Activity in Response to Extracellular Matrix Stimulation to Drive Cancer Cell Invasiveness.
Crottès D, Rapetti-Mauss R, Alcaraz-Perez F, Tichet M, Gariano G, Martial S, Guizouarn H, Pellissier B, Loubat A, Popa A, Paquet A, Presta M, Tartare-Deckert S, Cayuela ML, Martin P, Borgese F, Soriani O.
Cancer Res. 2016 Feb 1;76(3):607-18. doi: 10.1158/0008-5472.CAN-15-1465. Epub 2015 Dec 8.
PMID: 26645564

2015

12. Tumour-derived SPARC drives vascular permeability and extravasation through endothelial VCAM1 signalling to promote metastasis.
Tichet M, Prod’Homme V, Fenouille N, Ambrosetti D, Mallavialle A, Cerezo M, Ohanna M, Audebert S, Rocchi S, Giacchero D, Boukari F, Allegra M, Chambard JC, Lacour JP, Michiels JF, Borg JP, Deckert M, Tartare-Deckert S.
Nat Commun. 2015 Apr 30;6:6993. doi: 10.1038/ncomms7993.
PMID: 25925867

2014

13. Risk for nevus transformation and melanoma proliferation and invasion during natalizumab treatment: four years of dermoscopic follow-up with immunohistological studies and proliferation and invasion assays.
Pharaon M, Tichet M, Lebrun-Frénay C, Tartare-Deckert S, Passeron T.
JAMA Dermatol. 2014 Aug;150(8):901-3. doi: 10.1001/jamadermatol.2013.9411.
PMID: 24919481 No abstract available.

2013-2009

14. Metformin blocks melanoma invasion and metastasis development in AMPK/p53-dependent manner.
Cerezo M, Tichet M, Abbe P, Ohanna M, Lehraiki A, Rouaud F, Allegra M, Giacchero D, Bahadoran P, Bertolotto C, Tartare-Deckert S, Ballotti R, Rocchi S.
Mol Cancer Ther. 2013 Aug;12(8):1605-15. doi: 10.1158/1535-7163.MCT-12-1226-T. Epub 2013 Jun 5.
PMID: 23741061

15. The epithelial-mesenchymal transition (EMT) regulatory factor SLUG (SNAI2) is a downstream target of SPARC and AKT in promoting melanoma cell invasion.
Fenouille N, Tichet M, Dufies M, Pottier A, Mogha A, Soo JK, Rocchi S, Mallavialle A, Galibert MD, Khammari A, Lacour JP, Ballotti R, Deckert M, Tartare-Deckert S.
PLoS One. 2012;7(7):e40378. doi: 10.1371/journal.pone.0040378. Epub 2012 Jul 20.
PMID: 22911700 Free PMC article.

16. Imatinib triggers mesenchymal-like conversion of CML cells associated with increased aggressiveness.
Puissant A, Dufies M, Fenouille N, Ben Sahra I, Jacquel A, Robert G, Cluzeau T, Deckert M, Tichet M, Chéli Y, Cassuto JP, Raynaud S, Legros L, Pasquet JM, Mahon FX, Luciano F, Auberger P.
J Mol Cell Biol. 2012 Aug;4(4):207-20. doi: 10.1093/jmcb/mjs010. Epub 2012 Mar 31.
PMID: 22467682

17. SPARC functions as an anti-stress factor by inactivating p53 through Akt-mediated MDM2 phosphorylation to promote melanoma cell survival.
Fenouille N, Puissant A, Tichet M, Zimniak G, Abbe P, Mallavialle A, Rocchi S, Ortonne JP, Deckert M, Ballotti R, Tartare-Deckert S.
Oncogene. 2011 Dec 8;30(49):4887-900. doi: 10.1038/onc.2011.198. Epub 2011 Jun 20.
PMID: 21685937

18. The p53/p21Cip1/ Waf1 pathway mediates the effects of SPARC on melanoma cell cycle progression.
Fenouille N, Robert G, Tichet M, Puissant A, Dufies M, Rocchi S, Ortonne JP, Deckert M, Ballotti R, Tartare-Deckert S.
Pigment Cell Melanoma Res. 2011 Feb;24(1):219-32. doi: 10.1111/j.1755-148X.2010.00790.x. Epub 2010 Nov 17.
PMID: 20955243

19. Regulation of HLA class I surface expression requires CD99 and p230/golgin-245 interaction.
Brémond A, Meynet O, Mahiddine K, Coito S, Tichet M, Scotlandi K, Breittmayer JP, Gounon P, Gleeson PA, Bernard A, Bernard G.
Blood. 2009 Jan 8;113(2):347-57. doi: 10.1182/blood-2008-02-137745. Epub 2008 Oct 10.
PMID: 18849489